… analyze the clinical outcomes of FDC versus FEC regimes of amlodipine and atorvastatin
in … events in patients with concurrent hypertension and dyslipidemia. Simultaneously, drug …

… those with concomitant hypertension and dyslipidemia. The … amlodipine/atorvastatin has
the potential to improve patient … risk in selected patients, thereby improving clinical outcomes. …

… healthcare costs, and improves both drug compliance and clinical outcomes. Relatively few
… of amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia …

… However, the clinical outcomes of different FDC dosages remain unknown. This study … the
clinical outcomes of FDC regimens and the free combination of amlodipine and atorvastatin at …

… were prescribed with fixed dose combination of 5 mg amlodipine and 10 mg atorvastatin. …
-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/…

… still a debate that does not show consistent results.38, 39 This is because most … concomitant
antihypertensive therapy makes it difficult to clearly identify the BP-lowering effects of statins. …

… The concurrent administration of statins and antihypertensive … Combined high-intensity
statin and amlodipine lead to … in patients with dyslipidemia and uncontrolled hypertension is …

… and most frequently associated risk factors are hypertension and dyslipidemia (DL). Studies
… The concomitant presence of AH and DL has a multiplicative rather than an additive effect …

… concomitant … fixed dose combination (FDC) containing 10 mg atorvastatin to the 20-mg
strength formulation in 2.8%, as well as from the latter to the 40-mg strength in 1.4% of the patients…

… Fixed-dose combinations have the potential to improve … % of patients with concomitant
hypertension and dyslipidemia are … DBClinical outcomes in managed-care patients with coronary …